Our "singular drug" has multi-indications. Not mentioned is the possible 90 indications our "singular drug" can likely address. A rare platform drug.
This was a sucker-punch article obviously aimed at blunting the recent sp increase.
(6)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-